Key Insights by Petros Grivas from ASCO25

At ASCO 2025, Dr. Petros Grivas offered insightful commentary on several impactful studies that are shaping the future of genitourinary oncology. From novel perioperative approaches to innovative combination therapies, these highlights reflect the dynamic pace of research and the ongoing effort to refine and personalize cancer care. Below is a curated overview of key presentations that Dr. Grivas emphasized as particularly noteworthy during the conference.

Some of the ASCO 2025 Highlights Shared by Dr. Petros Grivas:

KN564 Trial – Naomi Haas:
A standout presentation by Dr. Naomi Haas on the KN564 trial evaluating pembrolizumab vs placebo in resected RCC. The results demonstrated significant DFS and OS benefit, consistent across subgroups, with no new safety signals. Data on subsequent therapies were also shared.

Zanzalitinib/Nivolumab ± Relatlimab – Jad Chahoud:
Echoing agreement with Dr. Yüksel Ürün, Dr. Jad Chahoud delivered a compelling presentation on first-line zanzalitinib/nivolumab ± relatlimab. The addition of relatlimab did not improve outcomes. The field now awaits results from the Phase 3 STELLAR-304 trial led by Dr. Sumanta K. Pal and colleagues.

PDIGREE Trial – Tian Zhang:
Congratulations to Dr. Tian Zhang and team for sharing early data from the PDIGREE trial. In collaboration with the Alliance, Drs. Toni Choueiri and Dan George, the study provided clear take-home points. Dr. Brian Rini raised an excellent question regarding the lower-than-expected CR rate with ipilimumab/nivolumab.

Axi/Nivo in Translocation RCC:
Kudos to the investigators tackling a rare tumor type. Axitinib/nivolumab shows activity in TFE/translocation RCC, whereas nivolumab monotherapy appears inactive. A bold and informative effort in an understudied area.

CREST Trial – Tom Powles:
Dr. Tom Powles delivered a stellar update on the CREST trial in BCG-naive NMIBC, showing that adding sasanlimab to BCG induction and maintenance improves EFS across patient subsets. However, PD-L1 status was not predictive. The data spark questions about real-world logistics, including clinic space and immune-related AE monitoring.

SURE-02 Trial – Andrea Necchi:
Dr. Andrea Necchi presented data from the SURE-02 trial combining sacituzumab govitecan (SG) and pembrolizumab, achieving a promising 44% cCR rate. This paves the way for larger bladder preservation trials. G-CSF prophylaxis is critical when using SG. Collaboration is ongoing with Dr. Monika Joshi on EA8231 (ECOG-ACRIN).

MIBC Perioperative Management – Maria J. Ribal:
Dr. Maria Ribal gave a comprehensive overview on perioperative management in MIBC, weighing pros and cons while presenting emerging data. Highlights included Phase 2 trials, NIAGARA, and anticipation for KN866, GC ± Nivo, and EV-IO studies.

Jonathan Rosenberg‘s Presentation:
A fantastic presentation by Dr. Jonathan Rosenberg capped off the highlights.

These highlights underscore the remarkable progress being made across a range of urologic cancers. Dr. Petros Grivas’ thoughtful reflections help contextualize the evolving treatment landscape and emphasize the importance of collaboration, innovation, and patient-centered care. As we look ahead, ongoing trials and real-world applications of these findings will be essential in translating science into survival.

Stay tuned as the landscape continues to evolve—these insights are just the beginning.
For more expert commentary and in-depth coverage from ASCO 2025 and beyond, follow OncoDaily for timely updates, interviews, and perspectives that matter.